Probiotic Composition for Pediatric Asthma via Gut-Lung Axis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for asthma and dyspnea, including bronchodilators and anti-inflammatory substances, do not effectively address the frequency and intensity of dyspnea events and are not well-suited for pediatric use, lacking direct intervention on respiratory symptoms.
Innovation Solution
A composition comprising specific strains of Lactobacillus salivarius (LS01) and Bifidobacterium breve (B632), optionally with additives, is administered orally to modulate the immune system and reduce respiratory symptoms in both allergic and non-allergic asthma phenotypes, particularly in pediatric patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bronchodilators and anti-inflammatory substances are used to treat asthma, then respiratory symptoms can be alleviated, but the frequency and intensity of dyspnea events are not effectively reduced
Solution Approach 1:
The patent introduces probiotic bacteria (Lactobacillus salivarius and Bifidobacterium breve) as intermediary agents that modulate the immune system through the gut-lung axis. These probiotics serve as mediators between the gastrointestinal microbiota and the respiratory system, indirectly reducing asthma symptoms and dyspnea frequency by regulating immune responses rather than directly acting on the lungs.
Solution Approach 2:
The patent replaces the conventional direct pharmacological approach (bronchodilators and anti-inflammatories acting on respiratory muscles and airways) with a biological modulation approach. Instead of mechanically or chemically forcing airway opening, the probiotics substitute by fundamentally altering the immune system's behavior through microbiota-mediated immunomodulation, thereby reducing the need for acute respiratory interventions.
2Ease of operation
If conventional asthma treatments are used, then inflammatory symptoms can be managed, but the treatments are not well-suited for pediatric use
Solution Approach 1:
The patent changes the fundamental parameter of treatment delivery from direct respiratory administration (inhalers, nebulizers) to gastrointestinal administration (oral probiotics). This parameter change makes the treatment much more suitable for pediatric use, as oral administration is easier for children and does not require coordination or proper inhaler technique, while maintaining or improving effectiveness through the gut-lung axis mechanism.
3Adaptability or versatility
If probiotic strains are used for skin diseases, then skin inflammation can be reduced, but their ability to treat respiratory disorders is not addressed
Solution Approach 1:
The patent demonstrates the universality of probiotic bacteria by showing that the same strains (Lactobacillus salivarius and Bifidobacterium breve) that effectively treat skin diseases can also effectively treat respiratory disorders like asthma. This multi-functionality is achieved through the probiotics' ability to modulate the immune system systemically, affecting both cutaneous and respiratory manifestations of allergic diseases.
Solution Approach 2:
The patent applies preliminary action by administering probiotics to modulate the immune system before asthma symptoms or dyspnea events occur. By establishing a beneficial microbiota profile in advance, the treatment prevents or reduces the frequency and intensity of acute respiratory episodes, rather than merely treating symptoms after they manifest.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly reduces the frequency and intensity of dyspnea events and asthma symptoms in pediatric patients, improving lung function and quality of life, while being well-tolerated and easy to administer.
Implementation Method 1
The restoration of an appropriate bacterial flora can reduce or even delay the onset and worsening of such allergic and autoimmune diseases.
Implementation Method 2
The use of strains of bacteria, Lactobacillus Salivarius (LS01) and, Bifidobacterium breve (BR03) for the treatment of skin diseases... shows that there is at least a partial remission due to the administration of the aforementioned strains of bacteria. The authors argue that evidence suggests that probiotic bacteria can modulate the immune system of the skin.
Data Source
Figure 1~2
AI summary
The present invention regards an isolated strain of bacteria belonging to the species Bifidobacterium breve (B632) DSM 24706 for use in the treatment of a disorder or an ailment or a disease of the respiratory airways and for use in the treatment of asthma and dyspnoea. Furthermore, the present invention further regards a mixture comprising or, alternatively, consisting of said isolated strain of bacteria, for use in the treatment of a disorder or an ailment or a disease of the respiratory airways and for use in the treatment of asthma and dyspnoea. Furthermore, the present invention regards a composition comprising said mixture and, optionally, at least one physiologically and/or pharmacologically acceptable additive and/or technological excipient, for use in the treatment of a disorder or an ailment or a disease of the respiratory airways; for use in the treatment of asthma and dyspnoea. Said isolated strain, said mixture and said composition being validly administered and used in the treatment of paediatric subjects.